Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > Deep learning algorithm accurately predicts macular degeneration progression
  • Geographic Atrophy

Deep learning algorithm accurately predicts macular degeneration progression

Ophthalmology 360

DeepGAze, a highly accurate and fully automated deep learning algorithm, has been developed to predict the progression from intermediate age-related macular degeneration (iAMD) to geographic atrophy (GA) within a year based on spectral-domain optical coherence tomography (SD-OCT) scans, according to a study.

The study demonstrates that DeepGAze’s predictive capabilities are not only impressive but also autonomous, as the inclusion of expert-annotated features did not enhance its performance.

This retrospective cohort study analyzed data from participants with iAMD at baseline who either progressed or did not progress to GA within the subsequent 13 months. The study used data from 3 distinct sets. The first set comprised patients from the Age-Related Eye Disease Study 2 AREDS2, while the second and third sets encompassed patients from routine clinical care at a tertiary referral center and associated satellites.

The algorithm, which was trained and cross-validated on Bioptigen SD-OCT volumes, demonstrated exceptional predictive capabilities. In data set 1, it achieved an area under the receiver-operator characteristic curve (AUROC) of 0.94, with an area under the precision-recall curve (AUPRC) of 0.90, sensitivity of 0.88, specificity of 0.90, positive predictive value, negative predictive value, and accuracy. Further validation on two external data sets (data sets 2 and 3) using Heidelberg Spectralis SD-OCT scans maintained high performance, with AUROCs of 0.94 and AUPRCs of 0.92.

The inclusion of expert-annotated SD-OCT features did not improve the model’s performance compared to the fully autonomous version, underscoring the algorithm’s self-sufficiency and robustness.

Reference
Dow ER, Jeong HK, Katz EA, et al. A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence Tomography. JAMA Ophthalmol. 2023.doi:10.1001/jamaophthalmol.2023.4659

 

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.”

Share

Related Content

  • Geographic Atrophy

Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk

  • Geographic Atrophy

Spotlight on IZERVAY®

  • Geographic Atrophy

Two-year GATHER2 data show sustained GA growth reduction with avacincaptad pegol

  • Conference Roundup

Floretina 2025: study shows reduced treatment burden with EYP-1901 for neovascular AMD

3 Mins Watch
  • Geographic Atrophy

Over half of patients with dry AMD developed advanced disease in long-term analysis

  • Geographic Atrophy

Monthly avacincaptad pegol reduces geographic atrophy lesion growth for up to 3.5 years

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon